Search Results - "Aarts, MJB"

Survival outcomes of patients with advanced melanoma from 2013 to 2017: Results of a nationwide population-based registry by van Zeijl, M.C.T., de Wreede, L.C., van den Eertwegh, A.J.M., Wouters, M.W.J.M., Jochems, A., Schouwenburg, M.G., Aarts, M.J.B., van Akkooi, A.C.J., van den Berkmortel, F.W.P.J., de Groot, J.W.B., Hospers, G.A.P., Kapiteijn, E., Piersma, D., van Rijn, R.S., Suijkerbuijk, K.P.M., ten Tije, A.J., van der Veldt, A.A.M., Vreugdenhil, G., van der Hoeven, J.J.M., Haanen, J.B.A.G.

“…The treatment landscape has completely changed for advanced melanoma. We report survival outcomes and the differential impact of prognostic factors over time…”
Get full text

POSC365 Health State Utilities of Advanced Melanoma Patients Treated in Clinical Practice in the Era of Novel Immuno- and Targeted Therapies by Franken, M, de Groot, S, van Dongen, A, Leeneman, B, Uyl-De Groot, CA, Aarts, MJB, van den Berkmortel, FWPJ, Blank, CU, Boers-Sonderen, MJ, van den Eertwegh, AJM, de Groot, JWB, Haanen, JBAG, Hospers, GAP, Kapiteijn, E, van Not, OJ, Piersma, D, van Rijn, RS, Stevense-den Boer, MAM, Suijkerbuijk, KPM, van der Veldt, AAM, Vreugdenhil, G, Wouters, MWJM, Versteegh, M, Blommestein, HM

Get full text

POSC366 Validity of the EQ-5D-3L and EQ-5D-5L in Advanced Melanoma by Franken, M, van Dongen, A, Leeneman, B, Uyl-De Groot, CA, Aarts, MJB, van den Berkmortel, FWPJ, Blank, CU, Boers-Sonderen, MJ, van den Eertwegh, AJM, de Groot, JWB, Haanen, JBAG, Hospers, GAP, Kapiteijn, E, de Meza, MM, Piersma, D, van Rijn, RS, Stevense-den Boer, MAM, Suijkerbuijk, KPM, van der Veldt, AAM, Vreugdenhil, G, Wouters, MWJM, Blommestein, HM, Versteegh, M

Get full text

Bishop score and risk of cesarean delivery after induction of labor in nulliparous women by VROUENRAETS, Francis P. J. M, ROUMEN, Frans J. M. E, DEHING, Cary J. G, VAN DEN AKKER, Eline S. A, AARTS, Maureen J. B, SCHEVE, Esther J. T

“…To quantify the risk and risk factors for cesarean delivery associated with medical and elective induction of labor in nulliparous women. A prospective cohort…”
Get full text

Abstract P3-15-01: Primary G-CSF Prophylaxis during the First Two Cycles Only or Throughout All Chemotherapy Cycles in Breast Cancer Patients at Risk of Febrile Neutropenia: Final Results from a Phase III Trial of the Dutch Breast Cancer Trialists Group (BOOG) by Aarts, MJB, Peters, FPJ, Dercksen, WMW, Mandigers, CMPW, Stouthard, J, Nortier, HWR, Kamm, YJL, van Warmerdam, LJC, van der Rijt, CCD, van Gastel, S, Joore, M, Kessels, A, Tjan-Heijnen, VCG

“…Abstract Background: In patients at risk of febrile neutropenia (FN), the highest incidence of FN is seen during the first chemotherapy cycles. This…”
Get full text